The circulating proteinase inhibitor α-1 antitrypsin regulates neutrophil degranulation and autoimmunity

Science Translational Medicine

Volumn 6, Issue 217, 2014, Pages

  Bergin, David A ^a   Reeves, Emer P ^a   Hurley, Killian ^a   Wolfe, Rebecca ^a   Jameel, Ramia ^a   Fitzgerald, Sean ^a   McElvaney, Noel G ^a  

^a BEAUMONT HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; IMMUNOGLOBULIN G ANTIBODY; LACTOFERRIN; MEMBRANE PROTEIN; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1;

ADULT; ALLELE; ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTICLE; AUTOIMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DEGRANULATION; FEMALE; HOMOZYGOSITY; HUMAN; HUMAN CELL; IN VITRO STUDY; INCIDENCE; INTRACELLULAR SIGNALING; LEUKOCYTE ACTIVATION; MALE; NEUTROPHIL DEGRANULATION; NEUTROPHIL GRANULE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR BINDING ASSAY;

ADOLESCENT; ADULT; ALPHA 1-ANTITRYPSIN; AUTOANTIBODIES; AUTOIMMUNITY; CELL DEGRANULATION; FEMALE; HUMANS; LACTOFERRIN; MALE; MIDDLE AGED; NEUTROPHILS; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84892546029     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3007116     Document Type: Article

References (100)

1. J. M. Stocks, M. Brantly, D. Pollock, A. Barker, F. Kueppers, C. Strange, J. F. Donohue, R. Sandhaus, Multi-center study: The biochemical efficacy, safety and tolerability of a new α1-proteinase inhibitor, Zemaira. COPD 3, 17-23 (2006).
2. 1-antitrypsin therapy in cystic fibrosis. Pediatr. Pulmonol. 41, 177-183 (2006).
3. 1- antitrypsin deficiency associated with emphysema. N. Engl. J. Med. 316, 1055-1062 (1987).
4. M. Wencker, B. Fuhrmann, N. Banik, N. Konietzko; Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen, Longitudinal follow-up of patients with α1-protease inhibitor deficiency before and during therapy with IV α1-protease inhibitor. Chest 119, 737-744 (2001).
5. J. Lieberman, Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: A new hypothesis with supporting data. Chest 118, 1480-1485 (2000).
6. 1-antitrypsin deficiency. Eur. Respir. J. 33, 1345- 1353 (2009).
7. E. W. Russi, Alpha-1 antitrypsin: Now available, but do we need it? Swiss Med. Wkly. 138, 191-196 (2008).
8. I. M. Nita, D. Serapinas, S. M. Janciauskiene, α1-Antitrypsin regulates CD14 expression and soluble CD14 levels in human monocytes in vitro. Int. J. Biochem. Cell Biol. 39, 1165-1176 (2007).
9. D. Subramaniyam, R. Virtala, K. Pawlowski, I. G. Clausen, S. Warkentin, T. Stevens, S. Janciauskiene, TNF-α-induced self expression in human lung endothelial cells is inhibited by native and oxidized α1-antitrypsin. Int. J. Biochem. Cell Biol. 40, 258-271 (2008).
10. S. Janciauskiene, S. Larsson, P. Larsson, R. Virtala, L. Jansson, T. Stevens, Inhibition of lipopolysaccharide-mediated human monocyte activation, in vitro, by α1-antitrypsin. Biochem. Biophys. Res. Commun. 321, 592-600 (2004).
11. I. Petrache, I. Fijalkowska, T. R. Medler, J. Skirball, P. Cruz, L. Zhen, H. I. Petrache, T. R. Flotte, R. M. Tuder, α-1 Antitrypsin inhibits caspase-3 activity, preventing lung endothelial cell apoptosis. Am. J. Pathol. 169, 1155-1166 (2006).
12. 1- antitrypsin. FEBS Lett. 300, 21-24 (1992).
13. M. Kalis, R. Kumar, S. Janciauskiene, A. Salehi, C. M. Cilio, Alpha 1-antitrypsin enhances insulin secretion and prevents cytokine-mediated apoptosis in pancreatic β-cells. Islets 2, 185-189 (2010).
14. C. Grimstein, Y. K. Choi, C. H. Wasserfall, M. Satoh, M. A. Atkinson, M. L. Brantly, M. Campbell-Thompson, S. Song, Alpha-1 antitrypsin protein and gene therapies decrease autoimmunity and delay arthritis development in mouse model. J. Transl. Med. 9, 21 (2011).
15. S. H. He, H. Xie, X. J. Zhang, X. J. Wang, Inhibition of histamine release from human mast cells by natural chymase inhibitors. Acta Pharmacol. Sin. 25, 822-826 (2004).
16. 1-Antitrypsin suppresses TNF-α and MMP-12 production by cigarette smoke-stimulated macrophages. Am. J. Respir. Cell Mol. Biol. 37, 144-151 (2007).
17. 1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients. Eur. Respir. J. 29, 240-250 (2007).
18. D. A. Bergin, E. P. Reeves, P. Meleady, M. Henry, O. J. McElvaney, T. P. Carroll, C. Condron, S. H. Chotirmall, M. Clynes, S. J. O'Neill, N. G. McElvaney, α-1 Antitrypsin regulates human neutrophil chemotaxis induced by soluble immune complexes and IL-8. J. Clin. Invest. 120, 4236-4250 (2010).
19. C. Grimstein, Y. K. Choi, M. Satoh, Y. Lu, X. Wang, M. Campbell-Thompson, S. Song, Combination of alpha-1 antitrypsin and doxycycline suppresses collagen-induced arthritis. J. Gene Med. 12, 35-44 (2010).
20. M. Hashemi, M. Naderi, H. Rashidi, S. Ghavami, Impaired activity of serum alpha-1-antitrypsin in diabetes mellitus. Diabetes Res. Clin. Pract. 75, 246-248 (2007).
21. E. C. Lewis, M. Mizrahi, M. Toledano, N. Defelice, J. L. Wright, A. Churg, L. Shapiro, C. A. Dinarello, α1-Antitrypsin monotherapy induces immune tolerance during islet allograft transplantation in mice. Proc. Natl. Acad. Sci. U.S.A. 105, 16236-16241 (2008).
22. E. C. Lewis, L. Shapiro, O. J. Bowers, C. A. Dinarello, α1-Antitrypsin monotherapy prolongs islet allograft survival in mice. Proc. Natl. Acad. Sci. U.S.A. 102, 12153-12158 (2005).
23. 1-Antitrypsin gene therapy modulates cellular immunity and efficiently prevents type 1 diabetes in nonobese diabetic mice. Hum. Gene Ther. 17, 625-634 (2006).
24. S. Song, K. Goudy, M. Campbell-Thompson, C. Wasserfall, M. Scott-Jorgensen, J. Wang, Q. Tang, J. M. Crawford, T. M. Ellis, M. A. Atkinson, T. R. Flotte, Recombinant adeno-associated virus-mediated alpha-1 antitrypsin gene therapy prevents type I diabetes in NOD mice. Gene Ther. 11, 181-186 (2004).
25. S. Toldo, I. M. Seropian, E. Mezzaroma, B. W. Van Tassell, F. N. Salloum, E. C. Lewis, N. Voelkel, C. A. Dinarello, A. Abbate, Alpha-1 antitrypsin inhibits caspase-1 and protects from acute myocardial ischemia-reperfusion injury. J. Mol. Cell. Cardiol. 51, 244-251 (2011).
26. W. G. Forssmann, Y. H. The, M. Stoll, K. Adermann, U. Albrecht, H. C. Tillmann, K. Barlos, A. Busmann, A. Canales-Mayordomo, G. Giménez- Gallego, J. Hirsch, J. Jiménez-Barbero, D. Meyer-Olson, J. Münch, J. Pérez-Castells, L. Ständker, F. Kirchhoff, R. E. Schmidt, Short-term monotherapy in HIV-infected patients with a virus entry inhibitor against the gp41 fusion peptide. Sci. Transl. Med. 2, 63re3 (2010).
27. J. Münch, L. Ständker, K. Adermann, A. Schulz, M. Schindler, R. Chinnadurai, S. Pöhlmann, C. Chaipan, T. Biet, T. Peters, B. Meyer, D. Wilhelm, H. Lu, W. Jing, S. Jiang, W. G. Forssmann, F. Kirchhoff, Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. Cell 129, 263-275 (2007).
28. L. Shapiro, G. B. Pott, A. H. Ralston, Alpha-1-antitrypsin inhibits human immunodeficiency virus type 1. FASEB J. 15, 115-122 (2001).
29. 1-antitrypsin deficiency. Eur. Respir. J. 34, 354-360 (2009).
30. 1- Proteinase inhibitor abrogates proteolytic and secretagogue activity of cystic fibrosis sputum. Respiration 62, 117-124 (1995).
31. N. G. McElvaney, R. C. Hubbard, P. Birrer, M. S. Chernick, D. B. Caplan, M. M. Frank, R. G. Crystal, Aerosol α1-antitrypsin treatment for cystic fibrosis. Lancet 337, 392-394 (1991).
32. A. M. Schols, W. A. Buurman, A. J. Staal van den Brekel, M. A. Dentener, E. F. Wouters, Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax 51, 819-824 (1996).
33. S. von Haehling, N. S. Hopkinson, M. I. Polkey, M. Niethammer, S. D. Anker, S. Genth-Zotz, Elevated TNFα production in whole blood in patients with severe COPD: The potential link to disease severity. Wien. Klin. Wochenschr. 121, 303-308 (2009).
34. F. Karpati, F. L. Hjelte, B. Wretlind, TNF-α and IL-8 in consecutive sputum samples from cystic fibrosis patients during antibiotic treatment. Scand. J. Infect. Dis. 32, 75-79 (2000).
35. D. Norman, J. S. Elborn, S. M. Cordon, R. J. Rayner, M. S. Wiseman, E. J. Hiller, D. J. Shale, Plasma tumour necrosis factor alpha in cystic fibrosis. Thorax 46, 91-95 (1991).
36. M. Silvestri, M. Bontempelli, M. Giacomelli, M. Malerba, G. A. Rossi, A. Di Stefano, A. Rossi, F. L. Ricciardolo, High serum levels of tumour necrosis factor-α and interleukin-8 in severe asthma: Markers of systemic inflammation? Clin. Exp. Allergy 36, 1373-1381 (2006).
37. A. Churg, R. D. Wang, C. Xie, J. L. Wright, α-1-Antitrypsin ameliorates cigarette smoke-induced emphysema in the mouse. Am. J. Respir. Crit. Care Med. 168, 199-207 (2003).
38. 1-antitrypsin inactivation and tumor necrosis factor α concentration in the synovial fluid of patients with rheumatoid arthritis. Arthritis Rheum. 37, 1723-1726 (1994).
39. S. Suter, U. B. Schaad, P. Roux-Lombard, E. Girardin, G. Grau, J. M. Dayer, Relation between tumor necrosis factor-alpha and granulocyte elastase-α1-proteinase inhibitor complexes in the plasma of patients with cystic fibrosis. Am. Rev. Respir. Dis. 140, 1640-1644 (1989).
40. A. A. Kruglov, A. Kuchmiy, S. I. Grivennikov, A. V. Tumanov, D. V. Kuprash, S. A. Nedospasov, Physiological functions of tumor necrosis factor and the consequences of its pathologic overexpression or blockade: Mouse models. Cytokine Growth Factor Rev. 19, 231-244 (2008).
41. M. A. Audrain, R. Sesboüé, T. A. Baranger, J. Elliott, A. Testa, J. P. Martin, C. M. Lockwood, V. L. Esnault, Analysis of anti-neutrophil cytoplasmic antibodies (ANCA): Frequency and specificity in a sample of 191 homozygous (PiZZ) alpha1-antitrypsin-deficient subjects. Nephrol. Dial. Transplant. 16, 39 -44 (2001).
42. M. Segelmark, A. N. Elzouki, J. Wieslander, S. Eriksson, The PiZ gene of alpha 1-antitrypsin as a determinant of outcome in PR3-ANCA-positive vasculitis. Kidney Int. 48, 844-850 (1995).
43. 1 antitrypsin and its polymers. Ann. Rheum. Dis. 70, 1851-1856 (2011).
44. H. Bruunsgaard, Physical activity and modulation of systemic low-level inflammation. J. Leukoc. Biol. 78, 819-835 (2005).
45. J. C. Oliver, L. A. Bland, C. W. Oettinger, M. J. Arduino, S. K. McAllister, S. M. Aguero, M. S. Favero, Cytokine kinetics in an in vitro whole blood model following an endotoxin challenge. Lymphokine Cytokine Res. 12, 115- 120 (1993).
46. I. C. van Riemsdijk-van Overbeeke, C. C. Baan, C. J. Hesse, E. H. Loonen, H. G. Niesters, R. Zietse, W. Weimar, TNF-α: mRNA, plasma protein levels and soluble receptors in patients on chronic hemodialysis, on CAPD and with end-stage renal failure. Clin. Nephrol. 53, 115-123 (2000).
47. R. Ferrari, T. Bachetti, R. Confortini, C. Opasich, O. Febo, A. Corti, G. Cassani, O. Visioli, Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation 92, 1479-1486 (1995).
48. S. Hope, I. Melle, P. Aukrust, N. E. Steen, A. B. Birkenaes, S. Lorentzen, I. Agartz, T. Ueland, O. A. Andreassen, Similar immune profile in bipolar disorder and schizophrenia: Selective increase in soluble tumor necrosis factor receptor I and von Willebrand factor. Bipolar Disord. 11, 726-734 (2009).
49. T. Spoettl, M. Hausmann, F. Klebl, A. Dirmeier, B. Klump, J. Hoffmann, H. Herfarth, A. Timmer, G. Rogler, Serum soluble TNF receptor I and II levels correlate with disease activity in IBD patients. Inflamm. Bowel Dis. 13, 727-732 (2007).
50. 2+. Proc. Natl. Acad. Sci. U.S.A. 87, 9472-9476 (1990).
51. A. Mócsai, Z. Jakus, T. Vántus, G. Berton, C. A. Lowell, E. Ligeti, Kinase pathways in chemoattractant-induced degranulation of neutrophils: The role of p38 mitogen-activated protein kinase activated by Src family kinases. J. Immunol. 164, 4321-4331 (2000).
52. R. E. Banks, M. A. Forbes, M. Storr, J. Higginson, D. Thompson, J. Raynes, J. M. Illingworth, T. J. Perren, P. J. Selby, J. T. Whicher, The acute phase protein response in patients receiving subcutaneous IL-6. Clin. Exp. Immunol. 102, 217-223 (1995).
53. H. Locht, T. Skogh, A. Wiik, Characterisation of autoantibodies to neutrophil granule constituents among patients with reactive arthritis, rheumatoid arthritis, and ulcerative colitis. Ann. Rheum. Dis. 59, 898-903 (2000).
54. P. Musiani, L. Lauriola, M. Piantelli, Inhibitory activity of alpha-1-antitrypsin bound to human IgA. Clin. Chim. Acta 85, 61-66 (1978).
55. 1-antitrypsin in vitro and reduces the association rate constant for neutrophil elastase. Respir. Res. 6, 146 (2005).
56. 1- Antitrypsin binds to and interferes with functionality of EspB from atypical and typical enteropathogenic Escherichia coli strains. Infect. Immun. 72, 4344-4350 (2004).
57. D. Serapinas, A. Narbekovas, J. Juskevicius, R. Sakalauskas, Systemic inflammation in COPD in relation to smoking status. Multidiscip. Respir. Med. 6, 214-219 (2011).
58. H. W. Niessen, A. J. Verhoeven, Differential up-regulation of specific and azurophilic granule membrane markers in electropermeabilized neutrophils. Cell. Signal. 4, 501-509 (1992).
59. P. Birrer, N. G. McElvaney, A. Rüdeberg, C. W. Sommer, S. Liechti-Gallati, R. Kraemer, R. Hubbard, R. G. Crystal, Protease-antiprotease imbalance in the lungs of children with cystic fibrosis. Am. J. Respir. Crit. Care Med. 150, 207-213 (1994).
60. W. Van Molle, C. Libert, W. Fiers, P. Brouckaert, Alpha 1-acid glycoprotein and alpha 1-antitrypsin inhibit TNF-induced but not anti-Fas-induced apoptosis of hepatocytes in mice. J. Immunol. 159, 3555-3564 (1997).
61. B. Zhang, Y. Lu, M. Campbell-Thompson, T. Spencer, C. Wasserfall, M. Atkinson, S. Song, α1-Antitrypsin protects β-cells from apoptosis. Diabetes 56, 1316-1323 (2007).
62. T. M. Eagan, T. Ueland, P. D. Wagner, J. A. Hardie, T. E. Mollnes, J. K. Damås, P. Aukrust, P. S. Bakke, Systemic inflammatory markers in COPD: Results from the Bergen COPD Cohort Study. Eur. Respir. J. 35, 540-548 (2010).
63. N. Takabatake, H. Nakamura, S. Inoue, K. Terashita, H. Yuki, S. Kato, S. Yasumura, H. Tomoike, Circulating levels of soluble Fas ligand and soluble Fas in patients with chronic obstructive pulmonary disease. Respir. Med. 94, 1215-1220 (2000).
64. H. L. Wright, B. Chikura, R. C. Bucknall, R. J. Moots, S. W. Edwards, Changes in expression of membrane TNF, NF-κB activation and neutrophil apoptosis during active and resolved inflammation. Ann. Rheum. Dis. 70, 537-543 (2011).
65. E. Brandt, F. Petersen, H. D. Flad, Recombinant tumor necrosis factor-alpha potentiates neutrophil degranulation in response to host defense cytokines neutrophil-activating peptide 2 and IL-8 by modulating intracellular cyclic AMP levels. J. Immunol. 149, 1356-1364 (1992).
66. O. E. Sørensen, P. Follin, A. H. Johnsen, J. Calafat, G. S. Tjabringa, P. S. Hiemstra, N. Borregaard, Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood 97, 3951-3959 (2001).
67. A. Mansell, A. Reinicke, D. M. Worrall, L. A. O'Neill, The serine protease inhibitor antithrombin III inhibits LPS-mediated NF-κB activation by TLR-4. FEBS Lett. 508, 313-317 (2001).
68. S. Bennouna, W. Sukhumavasi, E. Y. Denkers, Toxoplasma gondii inhibits Toll-like receptor 4 ligand-induced mobilization of intracellular tumor necrosis factor alpha to the surface of mouse peritoneal neutrophils. Infect. Immun. 74, 4274-4281 (2006).
69. E. Kitchen, A. G. Rossi, A. M. Condliffe, C. Haslett, E. R. Chilvers, Demonstration of reversible priming of human neutrophils using platelet-activating factor. Blood 88, 4330-4337 (1996).
70. N. R. Singh, A. Johnson, A. M. Peters, J. Babar, E. R. Chilvers, C. Summers, Acute lung injury results from failure of neutrophil de-priming: A new hypothesis. Eur. J. Clin. Invest. 42, 1342-1349 (2012).
71. D. R. Spriggs, M. L. Sherman, K. Imamura, M. Mohri, C. Rodriguez, G. Robbins, D. W. Kufe, Phospholipase A2 activation and autoinduction of tumor necrosis factor gene expression by tumor necrosis factor. Cancer Res. 50, 7101-7107 (1990).
72. M. Sato, T. Miyazaki, T. Nagaya, Y. Murata, N. Ida, K. Maeda, H. Seo, Antioxidants inhibit tumor necrosis factor-α mediated stimulation of interleukin-8, monocyte chemoattractant protein-1, and collagenase expression in cultured human synovial cells. J. Rheumatol. 23, 432-438 (1996).
73. M. A. Fiedler, K. Wernke-Dollries, J. M. Stark, Inhibition of TNF-α-induced NF-κB activation and IL-8 release in A549 cells with the proteasome inhibitor MG-132. Am. J. Respir. Cell Mol. Biol. 19, 259-268 (1998).
74. S. Borgmann, G. Endisch, S. Urban, T. Sitter, H. Fricke, A linkage disequilibrium between genes at the serine protease inhibitor gene cluster on chromosome 14q32.1 is associated with Wegener's granulomatosis. Clin. Immunol. 98, 244-248 (2001).
75. 1-antitrypsin PiZ allele and Wegener's granulomatosis. J. Intern. Med. 236, 543-548 (1994).
76. V. L. Esnault, A. Testa, M. Audrain, C. Rogé, M. Hamidou, J. H. Barrier, R. Sesboüé, J. P. Martin, P. Lesavre, Alpha 1-antitrypsin genetic polymorphism in ANCA-positive systemic vasculitis. Kidney Int. 43, 1329-1332 (1993).
77. M. E. Griffith, J. U. Lovegrove, G. Gaskin, D. B. Whitehouse, C. D. Pusey, C-antineutrophil cytoplasmic antibody positivity in vasculitis patients is associated with the Z allele of alpha-1-antitrypsin, and P-antineutrophil cytoplasmic antibody positivity with the S allele. Nephrol. Dial. Transplant. 11, 438-443 (1996).
78. G. Lominadze, D. W. Powell, G. C. Luerman, A. J. Link, R. A. Ward, K. R. McLeish, Proteomic analysis of human neutrophil granules. Mol. Cell. Proteomics 4, 1503-1521 (2005).
79. P. L. Masson, J. F. Heremans, E. Schonne, Lactoferrin, an iron-binding protein in neutrophilic leukocytes. J. Exp. Med. 130, 643-658 (1969).
80. H. Chikazawa, K. Nishiya, A. Matsumori, K. Hashimoto, Immunoglobulin isotypes of anti-myeloperoxidase and anti-lactoferrin antibodies in patients with collagen diseases. J. Clin. Immunol. 20, 279-286 (2000).
81. H. Locht, T. Skogh, E. Kihlström, Anti-lactoferrin antibodies and other types of anti-neutrophil cytoplasmic antibodies (ANCA) in reactive arthritis and ankylosing spondylitis. Clin. Exp. Immunol. 117, 568-573 (1999).
82. D. Caccavo, A. Rigon, A. Picardi, S. Galluzzo, M. Vadacca, G. M. Ferri, A. Amoroso, A. Afeltra, Anti-lactoferrin antibodies in systemic lupus erythematosus: Isotypes and clinical correlates. Clin. Rheumatol. 24, 381-387 (2005).
83. C. Roozendaal, G. Horst, K. Pogány, A. W. van Milligen de Wit, J. H. Kleibeuker, E. B. Haagsma, P. C. Limburg, C. G. Kallenberg, Prevalence and clinical significance of anti-lactoferrin auto-antibodies in inflammatory bowel diseases and primary sclerosing cholangitis. Adv. Exp. Med. Biol. 443, 313-319 (1998).
84. W. L. Gross, S. Hauschild, N. Mistry, The clinical relevance of ANCA in vasculitis. Clin. Exp. Immunol. 93 (Suppl. 1), 7-11 (1993).
85. S. T. Schmid, J. Koepke, M. Dresel, A. Hattesohl, E. Frenzel, J. Perez, D. A. Lomas, E. Miranda, T. Greulich, S. Noeske, M. Wencker, H. Teschler, C. Vogelmeier, S. Janciauskiene, A. R. Koczulla, The effects of weekly augmentation therapy in patients with PiZZ α1-antitrypsin deficiency. Int. J. Chron. Obstruct. Pulmon. Dis. 7, 687-696 (2012).
86. T. P. Carroll, C. A. O'Connor, O. Floyd, J. McPartlin, D. P. Kelleher, G. O'Brien, B. D. Dimitrov, V. B. Morris, C. C. Taggart, N. G. McElvaney, The prevalence of alpha-1 antitrypsin deficiency in Ireland. Respir. Res. 12, 91 (2011).
87. F. J. de Serres, I. Blanco, Prevalence of α1-antitrypsin deficiency alleles PI*S and PI*Z worldwide and effective screening for each of the five phenotypic classes PI*MS, PI*MZ, PI*SS, PI*SZ, and PI*ZZ: A comprehensive review. Ther. Adv. Respir. Dis. 6, 277-295 (2012).
88. M. Dahl, C. P. Hersh, N. P. Ly, C. S. Berkey, E. K. Silverman, B. G. Nordestgaard, The protease inhibitor PI*S allele and COPD: A meta-analysis. Eur. Respir. J. 26, 67-76 (2005).
89. 1- antitrypsin PI MZ heterozygotes: A meta-analysis. Thorax 59, 843-849 (2004).
90. A. W. Segal, O. T. Jones, Absence of cytochrome b reduction in stimulated neutrophils from both female and male patients with chronic granulomatous disease. FEBS Lett. 110, 111-114 (1980).
91. K. Saeki, M. Nakahara, S. Matsuyama, N. Nakamura, Y. Yogiashi, A. Yoneda, M. Koyanagi, Y. Kondo, A. Yuo, A feeder-free and efficient production of functional neutrophils from human embryonic stem cells. Stem Cells 27, 59-67 (2009).
92. D. A. Bergin, K. Hurley, A. Mehta, S. Cox, D. Ryan, S. J. O'Neill, E. P. Reeves, N. G. McElvaney, Airway inflammatory markers in individuals with cystic fibrosis and non-cystic fibrosis bronchiectasis. J. Inflamm. Res. 6, 1-11 (2013).
93. T. P. Carroll, C. M. Greene, C. A. O'Connor, A. M. Nolan, S. J. O'Neill, N. G. McElvaney, Evidence for unfolded protein response activation in monocytes from individuals with α-1 antitrypsin deficiency. J. Immunol. 184, 4538-4546 (2010).
94. J. Liu, J. L. Hu, B. W. Shi, Y. He, W. X. Hu, Up-regulation of p21 and TNF-α is mediated in lycorine-induced death of HL-60 cells. Cancer Cell Int. 10, 25 (2010).
95. I. Vega-Carrascal, E. P. Reeves, T. Niki, T. Arikawa, P. McNally, S. J. O'Neill, M. Hirashima, N. G. McElvaney, Dysregulation of TIM-3-galectin-9 pathway in the cystic fibrosis airways. J. Immunol. 186, 2897-2909 (2011).
96. -ΔΔCT method. Methods 25, 402-408 (2001).
97. P. Anton, J. O'Connell, D. O'Connell, L. Whitaker, G. C. O'Sullivan, J. K. Collins, F. Shanahan, Mucosal subepithelial binding sites for the bacterial chemotactic peptide, formyl-methionyl- leucyl-phenylalanine (FMLP). Gut 42, 374-379 (1998).
98. E. P. Reeves, M. Williamson, B. Byrne, D. A. Bergin, S. G. Smith, P. Greally, R. O'Kennedy, S. J. O'Neill, N. G. McElvaney, IL-8 dictates glycosaminoglycan binding and stability of IL-18 in cystic fibrosis. J. Immunol. 184, 1642-1652 (2010).
99. E. P. Reeves, K. Reiber, C. Neville, O. Scheibner, K. Kavanagh, S. Doyle, A nonribosomal peptide synthetase (Pes1) confers protection against oxidative stress in Aspergillus fumigatus. FEBS J. 273, 3038-3053 (2006).
100. S. Janusonis, Comparing two small samples with an unstable, treatment-independent baseline. J. Neurosci. Methods 179, 173-178 (2009).